Trilogy AB Acetabular Hip System Post Approval Study

Phase 4TerminatedNCT00715026

Zimmer Biomet31 enrolled

Overview

This is a post-approval study with prospective enrollment in the United States and a retrospective enrollment outside the United States to obtain functional, quality of life and radiographic data, which will facilitate assessment of the clinical performance of the Zimmer Trilogy AB Acetabular Hip System.

To obtain functional, quality of life and radiographic data to evaluate the clinical performance of the Zimmer Trilogy AB Acetabular Hip System in primary total hip replacement surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Osteoarthritis Avascular Necrosis Congenital Hip Dysplasia Traumatic Arthritis

Interventions

Trilogy AB Acetabular Hip Implant SystemDEVICE

Total hip replacement with ceramic on ceramic treatment surfaces.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non-obese patients * The patient is a good candidate for a primary hip arthroplasty using the Zimmer Trilogy AB Acetabular Hip System. * Patient is willing and able to give informed consent to participate in the follow-up program. * Patient is suitable for surgery and able to participate in the follow-up program. Exclusion Criteria: * Skeletally immature * Rheumatoid arthritis * Osteoradionecrosis * Infection * Nerve or muscle disease that may have a negative affect on gait or weight bearing * Loss of abductor musculature in the affected limb * Poor bone stock * Poor skin coverage around the hip joint * Rapid disease progression as obvious by joint destruction or bone absorption seen on x-ray * Previous total or cemented hemi-arthroplasty of the affected hip * Previous pinning or plating of the affected hip * Patients with heavy labor jobs or extreme activity levels * Patients who participate in sports activities or require deep flexion * Patients who are obese * Patients who have other disabilities * Patients who are unwilling or unable to give consent, or to comply with the protocol and follow-up program.

Locations (2)

Shrock Orthopedic Research

Fort Lauderdale, Florida, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Harris Hip Score

The Harris Hip Score was developed to assess hip disabilities and methods of treatment and has been in use for decades. It evaluates patients on the basis of pain, function, absence of deformity and range of motion. The Harris Hip Score could range from 0 to 100. Scores less then 70 are poor, scores 70 to 79 are fair, scores 80 to 89 are good, and scores 90 to 100 are excellent.

Time frame: Pre-op, 3 Month Post-Op and Annual Post-Op visits through 5 Years

Secondary Outcomes

Continued Assessment of Implant Survivorship and Incidences of Adverse Events.

A total of 37 Adverse Events were reported. There have been no UADEs reported in this study population. At the time of site closure all AEs were resolved or tolerated. Implant survivorship not reportable due to early study termination.

Time frame: At all follow-up visits through 5 Years and postcard follow-up 6 - 10 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.